reason report
ebitda pt
bottom line continu high convict
solid guidanc increas share repurchas
author dividend yield rais estim
pt repres ev ebitda multipl
averag ebitda solid ebitda
beat price margin improv swb suppli off-set
volum headwind challeng flu comp importantli
initi revenu guidanc repres top-lin
growth includ mission health ebitda guidanc
mm mm upper end normal
guidanc indic continu growth acceler see
surviv fittest best breed play portfolio asset secularli
attract market capit deploy optim across
inpati servic line occup ambulatori site
servic manag team execut deliv consist
differenti strategi compani insul
downsid risk macro econom slowdown given geograph
footprint competit posit drive outsiz share gain
especi commerci employ busi balanc sheet
solid leverag ratio strong cffo
smart capit deploy annual basi across share
repo capital-expenditure dividend rais ebitda
mm shi top end guidanc ebitda
mm reflect view continu yoy growth acceler
includ unannounc
beyond ss volum growth expect least
line growth guidanc secular tailwind attract
market outsiz market share gain build servic line
ambulatori asset contribut solid volum
perform volum miss flu comp headwind
though surgeri growth tepid expect exhibit
price growth look sustain upsid conserv
guidanc commerci payor mix acuiti continu surpris
upsid contract rate high mid-singl digit
medicar reimburs environ includ dsh tailwind
tailwind prove growth contract
similar rate improv exhibit
margin look pois expand cost effici
integr acquir asset offer upsid normal margin
outlook current model bp margin contract due
integr though revenu growth near high end
guidanc rang could lead margin leverag exhibit
compani inform svb leerink llc research
revenu million bad debt ep present ex one-tim item
ev/ebitda average
ebitda
net debt total capit
price-to-earnings lt ep growth
estimate lt ep growth compound-annual-growth-rate
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
portfolio market differenti insul compani
potenti macro econom downturn outsiz share gain
especi commerci employ market number
number market posit concentr across south se sw
note gain bp inpati market share
balanc sheet strong leverag cffo
solid quarter capit deploy strategi
differenti guid capital-expenditure invest
servic line ambulatori asset clinic technolog
drive outsiz market share gain level play field
 strategi balanc across new market maker boost
exist market posit build inpati servic
line outpati ambulatori asset mission health
expect close januari drive guidanc
growth also recent made ambulatori surgic center
acquisit austin tx expect continu activ
acut ambulatori exhibit
rais ebitda mm near high end
guidanc rang ebitda increas mm
assum revenu ebitda growth bp
margin expans note estim unannounc
 may reflect consensu exhibit
pt goe pt move
contempl ev ebitda averag
continu high convict solid guidanc increas
share repurchas author dividend yield rais estim pt
repres ev ebitda multipl averag
ebitda solid ebitda beat price margin improv swb
suppli off-set volum headwind challeng flu comp importantli initi
revenu guidanc repres top-lin growth includ mission health
ebitda guidanc mm mm upper end
see surviv fittest best breed play portfolio asset secularli
attract market capit deploy optim across inpati servic line
occup ambulatori site servic manag team execut
deliv consist differenti strategi compani insul downsid
risk macro econom slowdown given geograph footprint competit posit
drive outsiz share gain especi commerci employ busi
balanc sheet solid leverag ratio strong cffo smart
capit deploy annual basi across share repo capital-expenditure dividend
rais ebitda mm shi top end guidanc
ebitda mm reflect view continu yoy growth acceler
includ unannounc
beyond ss volum growth expect least line growth
guidanc secular tailwind attract market outsiz market share gain build
servic line ambulatori asset contribut solid volum
perform volum miss flu comp headwind though surgeri growth
tepid expect
compani report svb leerink estim
price growth look sustain upsid conserv guidanc
commerci payor mix acuiti continu surpris upsid contract rate high
mid-singl digit medicar reimburs environ includ dsh
tailwind tailwind prove growth contract
similar rate improv
yeah let attempt pleas finish year revenu per admit
look year-to-d same-facil basi benefit medicar updat
fourth quarter said continu benefit built good visibl
commerci contract expect see continu growth acuiti good payer mix
think year help strong commerci volum talk continu growth
acuiti left us littl bit kind expect see
realli see major chang go payer environ mayb somehow continu
trend go forward term plan would plan rang
hope continu growth acuiti good payer mix top side exceed
yoy net exchang
compani report svb leerink estim note ss commerci adjust admiss exclud impact exchang
margin look pois expand cost effici integr acquir
asset offer upsid normal margin outlook current model bp
margin contract due integr though revenu growth near high
end guidanc rang could lead margin leverag
compani report svb leerink estim
portfolio market differenti insul compani potenti
macroeconom downturn outsiz share gain especi commerci employ
market number number market posit concentr across south se
sw note gain bp inpati market share
balanc sheet strong leverag cffo solid quarter
capit deploy strategi differenti guid capital-expenditure
invest servic line ambulatori asset clinic technolog drive outsiz
market share gain level play field nfp competitor
 strategi balanc across new market maker boost exist market posit
build inpati servic line outpati ambulatori asset mission
expect close januari drive guidanc growth
also recent made acquisit austin tx expect continu activ
acut ambulatori
growth capital-expenditure
rais ebitda mm near high end guidanc rang
ebitda increas mm assum revenu ebitda growth
bp margin expans note estim unannounc
may reflect consensu
compani report svb leerink estim note mm
million except per shareheadlin guidanceiniti guidanceconsensussvb leerink estimatesnet ep per equival adjust ss top line growth normal baselin ex-hurricanesmedicar rate increas increas rate yoyacquisit tx acquisit savannah ga facil hurrican yoy impactoth opex core trendoper bp deterior acquisit integr svb leerink ebitda inc
compani report svb leerink estim note mm
compani report factset svb leerink research estim note ebitda includ unannounc may
compar consensu
pt goe pt move contempl ev ebitda
averag ebitda
driver adjust ss top growth unannounc unannounc transactionsacquisit mission health recent transactionssuppli expens core trend improv procur recent svb leerink ebitda leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net opex/net rev/ per adj inpati admiss adj admin inc
pt contempl ev/ebitda averag ebitda view
factset compani report svb leerink estim note mm except per share
trade consensu ev/ebitda
factset compani report leerink partner llc research estim note mm except per share
date valuat
price target base pro forma ebitda leverag post transact
debt repay
downsid risk valuat includ possibl delay medicaid expans current
non-expans state delay time sale hospit asset initi improv
physician product expens reduct exposur larg earn swing result
high leverag variou on-going legal proceed may result cash outflow
date valuat
primari valuat methodolog base rel ev/ebitda rel
ev/ebitda track function compani histori hospit group averag
assess potenti ev/ebitda expans next month base forward
forecast contempl underli fundament implic healthcar reform
base rate outperform price target base
ev/ebitda averag ebitda view
downsid risk valuat includ govern reimburs chang part drug
inpati outpati payment updat possibl legisl judici chang coverag
expans obamacar across medicaid expans exchang contract risk privat
manag plan consolid acceler shift value-bas care
date valuat
rate outperform price target base combin enterpris
valu ebitda multipl valuat base forward forecast contempl underli
fundament implic healthcar reform sum-of-the-part valuat rang
downsid risk valuat includ possibl delay medicaid expans current
non-expans state downsid risk leverag legisl regul cut government
commerci payer reimburs
date valuat
primari valuat methodolog base rel ev/ebitda rel
ev/ebitda track function compani histori hospit group averag
assess potenti ev/ebitda expans next month base forward
forecast contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
point potenti multipl expans along sector compani specif
catalyst expect greater potenti multipl expans dcf valuat point
significantli upsid peer current trade level base rate
outperform price target base ev/ebitda
downsid risk valuat includ possibl delay medicaid expans current
non-expans state acut care segment highli concentr la vega texa
cut govern commerci payer reimburs declin receiv collect
rate pay mix pressur behavior segment
incom statement mm except provis doubt net expensessalari oper total oper depreci incom ebit net interest pbt incom tax incom yoy incom attribut non-controlling net incom attribut net incom attribut share dilut yoy dilut yoy growth growth expense/net opex/net inc
